Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nobody’s watching.
Last I heard there is a court date in March or April 2024. That’s if it doesn’t get pushed again and again.
I haven't been watching.
Any court dates coming up?
Yes. This is a much better outcome than Rik stepping aside
Trading at virtually 0 dollars. Looks like it is over.
Well, good for you.
CNGREEN, LOL
So, We are out of business, right guys,,
Very glad I did takeoff my original investment plus a 20% profit.... Free ridding shares...
Sincerely feel bad for Sam thu
RSI38
I’ve been calling and speaking to him for years, and everything he’s ever been upbeat about, never happened!
Last time I called and spoke with him, he sounded upbeat. I wonder what the direction will be in the future here.
ANYBODY who is not toxic
Who would take his place?
There was no settlement. Rik doesn’t want to give up anything. Holding us, the company and our money hostage.
He could resign and end all of this, but he chooses to be selfish
"I'm just trying to save people from being suckered into losing every penny in a garbage sub-penny FRAUD"....
That ship has sailed.
OMG! I'M LAUGHING-SO-HARD...THAT'S-MAV!!LOL
THOSE ARE DIRECT QUOTES FROM maverick81 BEFORE NPHC CRASHED 99%!!!
OMG... I'M ACTUALLY TEARING UP FROM LAUGHING SO HARD!!!!
That's how insane and pathetic his posts were back in 2017/2018 when the stock crashed from $0.0068 to $0.0001 -- and all the while he was PUMPING the sh^t out of NPHC, claiming it was going to be "MULTIPLE PENNIES!"
BWAHAHAHAHAHAHAHAHAHAHAHAHA!!!!
MAV IS SUCH A TOTAL POS LIAR, PUMPER & FAILED MANIPULATOR!!!
You really need to read the post... He's quoting someone.
Thanks for taking the time to post the prices.
Are you mentally ill?
"Multi pennies is a logical PPS for NPHC... it is a good deal for a good stock... .004 is not even believable. It doesnt make sense and thats why some are scratching their heads wondering why... just like the guy looking and the lambo for sale at 5k.
Longs... dont get frustrated with the current PPS. Know that it is IRRELEVANT. Literally in one session we can break .01 and never look back. Remember that is a fact"
That is delusional - when is NPHC going to go to $0.01 - you really need help.
IG
Just send Deitsch a check and save the transaction fee.
Don't try to encourage others to invest in this junk.
There isn't any pressure building.
IG
I really didn't care what he said then,
and I don't give a shit now.
Go tell your dog. Maybe he cares.
AS NPHC WAS CRASHING, maverick81-SAYS-"MULTI-PENNIES-COMING"-&-MORE-LIES!!
MAV, A DESPERATE LIAR AND MANIPULATOR AT THIS POINT, STARTS BLAMING THE CRASH ON EVERYBODY POSSIBLE, FROM MANIPULATIVE TRADERS, FLIPPERS, AND EVENTUALLY YOU'LL SEE HIM BLAME THE MARKET MAKERS IN LATER POSTS!!
THIS IS JUST PATHETIC!!!
WHAT A LYING POS!!
AND THIS WAS THE OUTCOME:
WRONG AGAIN!! He SAID "10-20-BAGGER-FROM-HERE!"
"FROM HERE," ... THAT'S FROM $0.0066 !!!
Mav
THE MATH FOR THAT 10 BAGGER MEANS THE STOCK WOULD HAVE HAD TO HAVE GONE TO ALMOST $0.07 !!! HE EVEN SAID 20 BAGGER.... THAT'S $0.14 ---- HILARIOUS!!!!
SHOW ME WHEN NPHC WENT TO $0.07 !!!
BWAHAHAHAHAHAHAHAHAHAHAHA!!!
IT'S CALLED BASIC MATH!!
.0066 X 1000% = .066
THE SALIENT POINT, HOWEVER, IS THAT THE STOCK CRASHED AS LOW AS IT COULD POSSIBLY GO AFTER HIS PUMPING, THUS LOSING HIMSELF AND EVERY OTHER FOOL THAT FOLLOWED HIM ALL OF THEIR MONEY!!! THAT'S PATHETIC!!
HE NEVER APOLOGIZED!! HE NEVER ADMITTED TO HIS MISTAKES!! HE ONLY CONTINUED TO LIE, SHILL, AND PUMP FURTHER!!! HE IS A DISGUSTING HUMAN BEING!!! PERIOD!!
STOP DEFENDING HIM!!! OR IS THIS MAV'S "OTHER ACCOUNT!?" BWAHAHAHAHAHAHAHAAA
Dude, he said the stock would have a run 10 to 20 times the current value at the time. It had a run of 30 times the value.
WRONG! Chart SHOWS 98% CRASH!!-SEE-BELOW!!!
NO... MAVERICK81 WAS 100% WRONG!!! HERE IS THE CHART, IMMEDIATELY FOLLOWING WHERE I POSTED THE BEGINNING OF HIS RIDICULOUS PUMPING!! EARLY FEBRUARY, 2018!!!
THE STOCK CRASHED FROM $0.006 ALL THE WAY DOWN TO $0.0001... SO, EXPLAIN TO US HOW "UM... HE WAS RIGHT, YOU KNOW" -- HILARIOUS!! THIS IS HOW INSANE PEOPLE HERE CAN BE!!! DELUSIONAL!!
MAV LOST EVERY PENNY OF HIS INVESTMENT, ALL WHILE PUMPING THE NON-EXISTENT FUNDAMENTALS OF THE COMPANY, THEREBY LOSING EVERY SINGLE PERSON THAT STUPIDLY FOLLOWED HIM ALL OF THEIR MONEY!!!
98% LOSS... DOWN TO $0.0001 !!!!
MORE COMING FOLKS.... YOU WON'T BELIEVE WHAT YOU SEE!!!
Yep...only took 3 years and a lame pump for that to happen.
Then reality set in again
Feb 11 2021 0.0091 -0.00115 -11.22% 0.01 0.0118 0.0079 70,706,207
Feb 10 2021 0.01025 -0.00155 -13.14% 0.012 0.013 0.0095 45,419,825
Feb 09 2021 0.0118 0.00 +0.00% 0.0125 0.013 0.009 0
Feb 09 2021 0.0118 -0.0007 -5.6% 0.0125 0.013 0.009 73,619,264
Feb 08 2021 0.0125 0.00 +0.00% 0.0103 0.0139 0.009 0
Feb 08 2021 0.0125 0.0023 22.55% 0.0103 0.0139 0.009 119,436,625
Feb 05 2021 0.0102 0.0033 47.83% 0.0077 0.0117 0.0069 161,625,425
Feb 04 2021 0.0069 0.0014 25.45% 0.0057 0.007 0.0054 63,316,347
Feb 03 2021 0.0055 0.0005 10.0% 0.0055 0.0055 0.0046 37,355,225
Feb 02 2021 0.005 0.00 +0.00% 0.0046 0.00555 0.0044 0
Feb 02 2021 0.005 0.0004 8.7% 0.0046 0.00555 0.0044 21,617,841
Feb 01 2021 0.0046 0.00 +0.00% 0.00425 0.0048 0.004 0
Feb 01 2021 0.0046 0.0005 12.2% 0.00425 0.0048 0.004 32,215,487
Jan 29 2021 0.0041 -0.0002 -4.65% 0.00405 0.0044 0.0034 20,374,194
Jan 28 2021 0.0043 0.00 +0.00% 0.005 0.0051 0.0024 0
Jan 28 2021 0.0043 -0.0006 -12.24% 0.005 0.0051 0.0024 79,934,505
Jan 27 2021 0.0049 0.0006 13.95% 0.0039 0.005 0.0039 71,702,870
Jan 26 2021 0.0043 0.0014 48.28% 0.0029 0.0043 0.0028 55,888,611
Jan 25 2021 0.0029 0.00 0.0% 0.003 0.0034 0.0026 57,020,452
Jan 22 2021 0.0029 0.00 +0.00% 0.0028 0.003 0.0025 0
Jan 22 2021 0.0029 0.0002 7.4% 0.0028 0.003 0.0025 34,621,698
Jan 21 2021 0.0027 0.00 +0.00% 0.0024 0.0028 0.0022 0
Jan 21 2021 0.0027 0.0004 17.39% 0.0024 0.0028 0.0022 20,778,076
Jan 20 2021 0.0023 0.0001 4.55% 0.0024 0.0028 0.002 39,515,578
Jan 19 2021 0.0022 0.0006 37.5% 0.0017 0.0022 0.00165 69,212,352
Jan 18 2021 0.0016 0.00 +0.00% 0.0016 0.0016 0.0016 0
Jan 18 2021 0.0016 0.00 0.0% 0.0016 0.0016 0.0016 0
Jan 15 2021 0.0016 0.0001 6.67% 0.0021 0.0021 0.0016 39,548,245
Jan 14 2021 0.0015 0.00 0.0% 0.0015 0.0017 0.0014 36,149,047
Jan 13 2021 0.0015 0.00 0.0% 0.0015 0.0015 0.0013 28,149,659
Jan 12 2021 0.0015 -0.0001 -6.25% 0.0017 0.0021 0.0014 130,476,564
Jan 11 2021 0.0016 0.0003 23.08% 0.0013 0.0017 0.0012 62,714,138
Jan 08 2021 0.0013 0.00 0.0% 0.0012 0.0014 0.0011 28,519,639
Jan 07 2021 0.0013 0.00 +0.00% 0.0012 0.0013 0.0011 0
Jan 07 2021 0.0013 0.0002 18.18% 0.0012 0.0013 0.0011 18,926,393
Jan 06 2021 0.0011 0.00 0.0% 0.0012 0.0013 0.0011 8,718,905
Jan 05 2021 0.0011 0.00 0.0% 0.0011 0.0013 0.0011 13,376,443
Jan 04 2021 0.0011 -0.0001 -8.33% 0.001 0.0012 0.001 14,027,447
Um, he was right you know…
OH MAV, WE'VE "MARKED" THIS ONE, TOO---WOW!!!PUMPING-HAS-STARTED!!!
MORE COMING IN THE DAYS AHEAD...
Mav
NOW MAV IS STARTING TO GET DESPERATE...JUST-DAYS-LATER:
AS NPHC DROPPED DOWN TO $0.004 -- DOWN 30% !!! OUCH!!!
maverick81
Re: None
Monday, February 05, 2018 10:33:06 PM
Post# of 64083
Current market cap 8 mil...
NPHC IS VASTLY UNDERVALUED.
Play it however u want.
We are on the verge of a parabolic move north to our correct market cap and that's a FACT
Mav
OH... WAIT UNTIL YOU SEE MORE!!!!
Maverick81:"MARK THIS POST!" -From-Feb-02-2017---WOW!!
HERE'S WHAT MAV SAID ON FEB, 02/2017... WHEN NPHC WAS AT $0.006 !!!!
QUOTE:
maverick81
Re: None
WELL, THE STOCK CRASHED AND BURNED, FATALLY... AND THEN WHAT DID HE SAY?
STAY TUNED FOR MORE...
Maverick81 Showed Up-Again...
... when the stock had its run! He pumped and pumped with wild claims saying it was only the beginning! Then he ran away when the stock crashed again!
He's worse than a clown; he's an EVIL POS!
I'm looking forward to (as soon as I have the time) posting some of his "GREATEST HITS" of FAKE news, misleading garbage, LIES, and Pathetic and Shameless Pumping!!
The new iHub is GREAT! We can post the truth and post evidence of a poster's True Intent!
This means we'll probably be rid of that kind of slime here soon enough!
They relied on truthful and factual posts proving their evil behavior getting taken down!
Not any more!
Goofy, I recall when a few members began to doubt Rik, Maverick 81 vowed that if Rik turned out to be a scammer, he would become Rik's worst nightmare. Rik turned out to be a scam artist but Maverick disappeared.
Thinking
Nobody minds if one:Wishes/Hopes/Prays...
That's perfectly fine; coming here and Pumping, pushing lies and nonsense, however, to try and pursued people to buy, knowing full well what you're saying isn't true or possible... is flat out EVIL! And that kind of behavior needs to be called out! And those people should be shamed away from these Boards. And it looks like that can happen now with the apparent new rules.
So, come on Maverick81 and your ilk, bring on your garbage, and I'll post your history of total and complete FAILURE!!!
Wish, hope pray or dream.
Nothing wrong with that.
I sure hope all the negative comments are all wrong or not relevant as to where the stock price might go. I have a right to wish, hope and pray.
THIS GUY, maverick81,LOST-PEOPLE-HERE-FORTUNES!!!
THIS MAVERICK81 LOSER USED TO COME ON THIS BOARD EVERY DAY TELLING PEOPLE THAT NPHC WAS GOING TO MAKE PEOPLE MILLIONAIRES, WHILE LYING ABOUT HOW MUCH HE HAD MADE ON NUMEROUS SUB-PENNY STOCKS!
I REPEATEDLY ASKED HIM TO POST THE TRADE SLIPS TO PROVE IT... OF COURSE HE NEVER DID!!
MY POSTS WERE CONTINUALLY TAKEN DOWN... WHICH COST UNSUSPECTING AND UNSOPHISTICATED "INVESTORS" (GAMBLERS) FORTUNES!!!
THIS IS JUST A PARTIAL LIST OF STOCKS HE CLAIMED HE BOUGHT HUGE POSITIONS IN, ON BOARDS ON IHUB, TAKEN FROM HIS OWN POSTING HISTORY!!!
EVERY SINGLE STOCK COMPLETELY COLLAPSED AND BECAME WORTHLESS!!!
I WILL KEEP REPLYING TO HIS INSANE -- AND FLAT OUT EVIL -- POSTS ABOUT HOW STUPID WE ALL WERE FOR NOT INVESTING IN NPHC!!!
FACT: WE WERE TOLD THIS ON FEB 2/2018 ($.OO6):
WHEN STOCK PRICE WAS AT .006!!!
maverick81 Member Level Friday, 02/02/18 10:32:46 AM
Re: None 0
Post # of 35670
Buckle up my friends...
NPHC is ready for next leg UP
Mav’s MASSIVE STOCK LOSSES-MUST SEE!
NWAV (Delested); EHOS (Delisted); ISBD(G)[Delisted]; IBRC (.0001);
FLSR (.0002); DIGX (.0003); MCGI (.0001); NPHC (.0003); VGID (.0007);
TXTM (.0009);NYXO; ICNB; KAYS; CSOC; UAMM; WDRP; TXTM; PAOG; RSII; FORC; ADHC; ICLD
CHECK OUT HIS HISTORY FROM HIS LAST PAGE AND SEE THE MASSIVE LOSSES HE HAS TAKEN AND HOW HE HAS SIMPLY FOLLOWED OTHERS' RECOMMENDATIONS AND BLINDLY THROWN MONEY AT LOSERS!!
This Guy's Past Posts-Are-a-MUST-READ!
Thanks ThinkingOutLoud:
Anyone foolishly thinking of gambling on NPHC should go through some of ThinkingOutLoud's incredibly thoughtful and informative past posts on Rik (Criminal CEO) and the company.
Let's just say that we've said many of the same things, but he is much more Diplomatic than I am! lol
And I seem to recall some pretty good knowledge and insights into Rik beyond just casual observations or publicly known information...
Hey Goofy R,
Thanks for your gracious greeting! I swing by now and then to chatch up. Thanks again for your patience and persistance.
Thinking
Hey Bud, Welcome-Back-For-The-$0.000001-Party!!lol
I stayed away for quite a long time as well, but checked in and still saw the same Lunatics trying to Pump this sucker and lure in unsophisticated "gamblers!"
I think management has changed the rules, because I -- and a couple others -- have been able to actually post some hard facts and histories of the Clowns who have been consistently pumping this garbage, and the posts don't come down for long, or don't come down at all.
So, if any more of these Clowns try and pretend that they've made money on sub-penny stocks, when in fact they have an abysmal track record, I will expose them!
And when I quote their own historical stupidity, it seems to stay up!
Maybe now some people will be saved from these POS and not lose as much money...
Aplology accepted. Thanks for the patience of Goofy and I-glow.
I used to be a leader in the MLM industry (I'm now happily retired). That's how I met and learned about Piccolo. We can judge a person by the friends he keeps. When Rik partnered with Piccolo, my jaw dropped: https://behindmlm.com/companies/vista-network-sues-phillip-piccolo-and-associates-for-fraud/.
I felt it would be irresponsible of me NOT to spread the warnings. I guess some heeded my alerts and saved money, while many ignored me and lost a bunch.
Thinking
I still want to apologize to you directly…
I’m sorry for attacking and vilifying you, you were ABSOLUTELY right!
It doesn’t matter how great the company and its IPs are, it all comes down to the character of the CEO and Rik is of very low moral character.
Hey Rango, Thanks for the belated recognition! I’ve posted my alerts with supporting links since 2017. The red flag for me was when Rik aligned himself with Phil Piccolo, who I met personally. Complainers labeled him, “A one man crime wave”. So, that was it for me!
Thinking
Do you remember the tune in one of the segments in Sesame Street;
One of these things is not like the others
One of these things doesn't belong
Knowing, or not knowing, isn't necessarily predicated on intelligence.
NPHC: NOV. 4, 2009--VERY INTERESTING-POST-FROM-2009:
JUST CLICK ON THE POST I'M REPLYING TO...
IT EXPLAINS A LOT!!! LOL
"picked up more shares today."
YUP!!"ADDING FROM SEPT. 2009"--CONFIRMED!!!NPHC!!!
cngreen
Re: goforthebet post# 717
Wednesday, September 23, 2009 7:33:32 PM
Post# of 64067
definately!! I keep adding as well.
SEPT. 2009 POST FROM CNGREEN:"YOUR[SIC]-LOOKING-AT-$10.36-SHARE-PRICE!!LOL
FULL QUOTE:
cngreen
Re: Ely post# 471
Wednesday, September 16, 2009 9:56:18 AM
Post# of 64065
some numbers for everyone. say they sell 30 millions units in their first year. (just the otc and US sales) i would think they would be minimally making 3-4 dollars on each unit. so your looking at 90-120 mm in net profit. with 220 mm shares outstanding gives you a per share worth .41-.545 without any forward multiple p/e. now it looks like the industry p/e multiple is about 19. so your looking at 7.76-10.36 per share price. damn im good!!!And thats just with otc cobroxin!!!
now think about the other countries nutrapharma is getting into and the prescription version coming out next year and the other drugs in the pipeline.
stock of a lifetime.
Luna Tic: You're not making any sense...how-about-some-context-here...
... So some of us can figure out what you're trying to say.
If they're not questions (without question marks), then what are they?
You're not crying, you're venting.
It's good for the soul.
You’re right, I’ll stop being a crybaby
These may look like questions...They're not.
What can nonvoting shareholders do to protect the assets from the CEO
What are the rights of shareholders re:conserving corporate assets
Why is everyone weeping over lost money and doing nothing
Why wouldn't anyone who defended this scum, man up and stop being a crybaby
Why hasn't anyone looked to real solutions
Isn't it time to actually give up the political demagoguery and state intent
Followers
|
499
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
64411
|
Created
|
05/04/06
|
Type
|
Free
|
Moderators |
Nutra Pharma Corp. (OTC: NPHC) is a biopharmaceutical company engaged in the acquisition, licensing and marketing of homeopathic treatments and ethical drugs for the management of pain, neurological disorders, cancer, auto-immune and infectious diseases. Nutra Pharma, through its RectoPharm subsidiary, carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process ReceptoPharm is developing technologies for the production of drugs for HIV and multiple sclerosis (MS), and also offers small and start-up biotech companies a full range of contract research services.
Investment Highlights
Corporate Strategy
Nutra Pharma's over-the-counter (OTC) products allow the company to achieve profitability and fund longer-term clinical trials in the therapeutic area. The therapeutics address a market size of > $10 billion, while the OTC products segment addresses a market size of $200 million - $500 million.
Reducing Risk
Nutra Pharma's strategy aims to optimize risk and return. At present, the company has a line of OTC products that bring in cash. This revenue will not only help fund development of the company's therapeutic line but, since sales of the OTC line and therapeutic line are uncorrelated, will result in a smoother revenue stream. By having what is, essentially, two businesses under one roof, Nutra Pharma mitigates risk to shareholders.
Revenue in the Short-term from OTC products
The OTC line comprises a number of analgesics. In October 2009, Nutra Pharma launched its first, called Cobroxin®, an over-the-counter pain reliever designed to treat moderate to severe chronic pain. In May 2010, the company launched its second consumer product, called Nyloxin®, an over-the-counter pain reliever that is a stronger version of Cobroxin.® And in December 2014, it launched Pet Pain-Away, an over-the-counter pain reliever designed to treat pain in cats and dogs. Nyloxin is currently being distributed both domestically and internationally via network marketing through the nationwide distributor Lumaxa.
Maximizing Return with a High-Value Therapeutic Line
Through its wholly owned subsidiary, ReceptoPharm, Inc., Nutra Pharma conducts drug discovery research and development activities. Nutra Pharma's R&D pipeline consists of several novel therapies in various stages of development to prevent and or treat multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN), herpes, and rheumatoid arthritis (RA). And the company is pursuing, aggressively, regulatory approval for these treatments.
Nyloxin
Nyloxin is an anti-inflammatory, non-toxic, non-narcotic, non-addictive, non-steroidal analgesic designed for chronic pain relief. It was first launched as an oral spray for treating back pain, neck pain, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, arthritis pain and pain from repetitive stress.
Since the beginning of 2014, it has been moved by the over 3,000 distributors in the Lumaxa network. Nutra Pharma is approved to distribute Nyloxin in India and is currently negotiating with large distributors throughout the region. Nutra Pharma is also working with several potential distributors in China and expects orders in India and China in the near future.
Nyloxin is clinically proven to treat Stage 2 (moderate to severe) and Stage 3 (severe) chronic pain. It is safe, non-narcotic and non-addictive, and does not impair cognitive function. Nyloxin is available in three strengths and 12 SKUs. In Regular Strength, Nyloxin is offered as an oral spray, a topical roll-on, and a topical gel. These same three preparations are offered in Extra Strength. The company also plans a 'Military Strength' Nyloxin for U.S. government buyers and military personnel.
Nyloxin Advantage
Jeff Gottfurcht is the first person in the world with rheumatoid arthritis to scale Mount Everest. Jeff reached the summit on May 14, 2011. He took Nyloxin with him as his pain reliever of choice.
Testimonials
Nyloxin Topical Gel I'm a massage therapist I have incorporated Nyloxin into my pain therapies with unbelievable results. I believe in this product so much that I became a distributor just so my clients can live pain free. - Steve Smith | |
Nyloxin Extra Strength Topical Gel I have never written a testimonial before. I have to tell you I am completely amazed at how well this product has worked for me. I have been on hydrocodone for years. Four days after taking this I have not needed it. I truly am shocked at the difference this has made in my pain. I have already reordered! - Elyse Feldberg | |
Nyloxin Oral Spray I am amazed at how well the Nyloxin spray has worked for me. I have had headaches for years, which sometimes turn to migrains. I have done biofeedback, been in the medical care of neurologists, and gone through testings, nothing I have tried has ever gotten rid of my headaches for any length of time, until I tried the Nyloxin spray. I even went to the mountains last weekend at 6,000 feet, for 3 days without a headache the whole time, I don't remember that ever happening. I am sold on this product. - Nancy Leamons |
*Some of the testimonials listed here may be from MyNyloxin Independent Entrepreneurs who may receive compensation which is received based on the sale of Nyloxin products."
Pet Pain-Away
Pets Owned in the U.S.: 95.6 million cats, 83.3 million dogs
The market for pain relief in dogs and cats is more than $200 million.
Millions of pets suffer from acute or chronic pain. While acute pain is a normal sensation triggered in the nervous system to alert your pet of possible injury and the need to take it easy, chronic pain is different, chronic pain persists. Pain signals keep firing in the nervous system for weeks, months, even years.
Historically, pain relief products for pets have been shown to cause other significant healthcare concerns and side effects.
Today, cobra venom is successfully being used for treating various forms of pain, autoimmune and neurological disorders. The Nutra Pharma subsidiary, ReceptoPharm, and other researchers have definitively proven that extracts from cobra venom contain constituents that control pain and inflammation in animals.
Pet Pain Away provides all-natural anti-inflammatory analgesic pain relief that is non-toxic, non-narcotic, non-steroidal and contains no aspirin or acetaminophen. Safe to use on pets, it treats conditions that cause chronic pain in animals.
Current Medical Research of the Available Remedies
Current pain relief products for pets such as NSAIDs (just for dogs) such as Carprofen (Novox or Rimadyl), Deracoxib (Deramaxx), Etodolac (Etogesic), Firocoxib (Previcox), Meloxicam (Metacam ) or Tepoxalin ( Zubrin) have been shown to cause kidney, liver, or digestive problems. Cats do not tolerate NSAIDs of any kind well. The only approved NSAID for cats in the United States is meloxicam and it is only approved for a single post-surgical injection to relieve pain. The dose must be exactly correct for the cat's weight. If it is given longer to cats, it often causes severe kidney damage.
Other medications such as Amantadine, Gabapentin and Tramadol may cause upset stomach, decreased heart rate, panting, and constipation. Veterinarians may prescribe stronger opiates only for a short periods. They usually don't prescribe steroids for pain, as they can have serious side effects. Veterinarians are usually hesitant to utilize pain therapies in companion animals because of the following: significant side effects, including nausea, vomiting, drowsiness, itching, constipation and respiratory depression; buildup of tolerance to analgesic requiring higher dosage over time to experience same effect; addictive properties that include severe withdrawal symptoms.
Therapeutic Pipeline
ReceptoPharm's research and development pipeline consists of several novel therapies in various stages of development to prevent and or treat multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN), herpes, rheumatoid arthritis (RA) and pain.
Abbreviations
Phase 1 (P-I), Phase 2 (P-II), Phase 3 (P-III)
RPI-78M
RPI-78M is derived from alpha-cobratoxin (α-CTX) by an oxidative procedure. Alpha-cobratoxin is the primary neuroactive peptide found in the venom of Asiatic cobras, and it represents the single active ingredient in the formulation under investigation. RPI-78M compares favorably with competing products. It lacks measurable toxicity, but is still capable of attaching to and affecting the target site on the cells. This means that patients cannot overdose.
Following years of investigations in humans and animals, it has displayed no serious adverse side effects. Patients experience symptomatic improvements, usually within six months of therapy. RPI-78M is extremely stable and resistant to heat, and so has a long shelf life. The drug's stability has been determined to be over four years at room temperature. It is easy to administer as a daily intramuscular injection (mcg dosing). RPI-78M has completed two trials for its use to treat adrenomyeloneuropathy (AMN). And at present, there are about 300 multiple sclerosis patients on open-label trials with RPI-78M.
RPI-MN
Nutra Pharma has received Orphan Drug Status from the FDA for RPI-78M as a candidate for the treatment of juvenile MS. Nutra Pharma is actively seeking collaborative research partners for early stage trials of RPI-78M in the treatment of juvenile multiple sclerosis (MS). The company has already been in contact with potential researchers, hospitals and sites of care for the purpose of moving forward with phase I/II clinical studies.
Nutra Pharma believes that RPI-78M provides an entirely new approach to the treatment of auto-immune diseases, including MS. As an immuno-modulating agent and not an immunosuppressive, RPI-78M could be a disruptive new drug entity in the autoimmune disease space. In previous open-label studies, RPI-78M has shown consistent symptomatic improvements within a period of less than six months in all stages of MS. The recently received Orphan Drug designation from the FDA allows the company to fast-track efforts through the clinical process. Based on existing clinical experience with RPI-78M, Nutra Pharma is confident that it can receive accelerated approval in a relatively short time-frame (expected in as little as 22-26 months).
RPI-78
Market Opportunity
According to the Centers for Disease Control and Prevention (CDC), there are currently about 1.2 million persons in the United States over the age of 13 who are human immunodeficiency virus (HIV) infected. Over the past 10 years the number of people living with HIV has increased. The incidence of new HIV infections has remained fairly stable, however, at about 50,000 new cases every year. As yet there is no cure for HIV: no compound has been isolated that kills the pathogen. But antiretroviral therapies (ART) can reduce the ability of the virus to reproduce and so keep infection at a level that does not overwhelm the immune system. The World Health Organization (WHO) estimates that, currently, there are about 37 million people worldwide living with HIV. The market size of antiretroviral therapies is estimated to be around $15 billion.
Like HIV, multiple sclerosis (MS) occurs when the immune system malfunctions. MS develops when the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between the brain and the rest of the body. The National Multiple Sclerosis Society estimates that about 2.3 million people are affected by MS worldwide. The market size of the MS drug market is about $16.7 billion. Adrenoleukodystrophy (AMN), also known as Schilder's disease and sudanophilic leukodystrophy, is another condition in which the myelin sheath is damaged. The AMN market has the potential to reach $400 million after the launch of an effective treatment. The Herpes Simplex Virus (HSV) affects thousands. According to the CDC, in 2013, some 306,000 persons visited a doctor for the first time in connection with a herpes condition. And the CDC also reports that, in 2007, about 1.5 million people in the U.S. were living with rheumatoid arthritis.
Management
Nutra Pharma is led by a management team comprised of highly experienced and educated professionals with a strong track record of excellence. This leadership is well-equipped to advance Nutra Pharma's therapeutic pipeline and increases distribution of its OTC products internationally.
Rik J. Deitsch - Chairman and Chief Executive Officer
Rik Deitsch holds both a B.S. in chemistry and an M.S. in biochemistry, and has conducted clinical and laboratory research in collaboration with scientists at Duke University Medical Center and the Cleveland Clinic. Deitsch is the author of two books and is an adjunct professor, teaching several courses for Florida Atlantic University's College of Business and Continuing Education Department.
Stewart Lonky, MD MBA - Director - Audit & Compensation Committees
Stewart Lonky is board certified in internal medicine, pulmonary and critical care medicine. He has published over a dozen articles in the peer-reviewed literature. Stewart is the former chief medical officer of a medical device company that developed diagnostic products for the early diagnosis of cervical and oral cancer. In that role, his duties included the direction of clinical research and the ultimate clearance of three new diagnostic devices by the U.S. Food and Drug Administration (FDA).
Harold H. Rump - Director
Harold Rump holds a B.S. from the United States Naval Academy. He is the former president, and director of Biogenix, Inc., a company involved with research and development of antiviral peptides from cobra venoms, including clinical trials under FDA-issued Investigational New Drug applications.
Garry R. Pottruck, CPA - Director - Chairman, Audit & Compensation Committees
Garry Pottruck is a CPA and financial expert on the NPHC's board of directors. Previously he served as chief accounting officer/controller at Scopas Technology Company, Inc., a NASDAQ-listed, development stage biotechnology research and development organization. He was, also, a principal and manager in the firm Argy, Wiltse & Robinson, PC ("Argy"), headquartered in McLean, Virginia.
Nutra Pharma Corporation | QualityStocks Investor Relations |
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Contact :
phone 954-509-0911
Email investor.relations@nutrapharm.com
12502 West Atlantic Bvld.
Coral Springs, FL 33071
Shares outstanding 442,185,921 as of May 23,2017.
Shares outstanding 1,233,519,298 as of July 20,2017.
http://www.otcmarkets.com/stock/NPHC/profile
Nutra Pharma Corp. (OTCBB: NPHC) http://www.NutraPharma.com is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. |
ReceptoPharm is an innovative biopharmaceutical drug discovery company developing proprietary therapeutic protein products primarily for the prevention and treatment of viral, autoimmune and neurological diseases in humans, including Adrenomyeloneuropathy (AMN), Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Pain, and Myasthenia Gravis (MG), and Human Immunodeficiency Virus (HIV). Drug Development The emphasis of ReceptoPharm's approach to drug discovery and the development of new therapeutic agents is based upon specialized receptor-binding proteins found in nature. » Learn More CRO Services ReceptoPharm offers a full range of contract services catering to start-up and small biotechnology companies. These services include pre-production studies, contract manufacturing services, US & EU regulatory support, and quality systems/GMP certification. ReceptoPharm is a wholly owned subsidiary of Nutra Pharma Corporation. |
Designer Diagnostics is a biotechnology sales and marketing company founded for the sale of diagnostics testkits for infectious diseases. Designer Diagnostics Test Kits provide a highly cost effective, highly efficient, low infrastructure solution for identifying and testing sensitivity of Nontuberculous Mycobacteria (NTM) that are capable of utilizing paraffin wax as a sole carbon source or those that are hydrophobic. Additionally Designer Diagnostics provides an efficient solution for the rapid identification and sensitivity testing of Tuberculosis (TB). Designer Diagnostics is a wholly owned subsidiary of Nutra Pharma Corporation. |
Cobroxin/Nyloxin TV Commercials and Advertising |
Here is a YouTube clip from 2013 showing the product: |
Nutra Pharma (NPHC.OB) RECENT NEWS | |||||
SOURCE: Nutra Pharma Corporation
|
ADDITIONAL NUTRA PHARMA INFORMATION |
12/10/09 Webinar from Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation:http://a40.video2.blip.tv/5350002509400/Vpoole-NHPCPresentationByCEO594.wmv?bri=11.6&brs=126 |
CHECK OUT THE Nutra Pharma Blog FOR MORE INFO ON THE WORLD MONEYSHOW CONFERENCE! |
|
Nutra Pharma (NPHC.OB) PATENTS |
U.S. Patent No. 5,989,857, which was granted in November 1999 with 10 claims.U.S. Patent No. 6,670,148, which was granted in December 2003, with 9 claims. The patent further describes the method for preparing a bioactive peptide (protein) found in cobra venom, in a stable, inactivated form, by treating the peptide with ozone.Buccal Delivery System, on which a patent is pending. This application describes a throat spray that permits efficient delivery of the modified peptide drugs to the body through oral mucosa.Technology contained in one pending U.S. patent application for the further development of bioactive peptides in cobra venom for use in the treatment of HIV and MS.Technology contained in two pending U.S. patent applications for Immunokine Composition and Method, which describes a method for developing modified peptides from alpha-cobratoxin.Technology contained in two patents pending for the topical delivery of our proprietary wound healing treatment, which was developed in conjunction with Bio Therapeutics. One of these products is in the form of an ointment style skin protectant and the other a foaming aerosol. |
R&D Pipeline | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
During our second quarter of 2015 and thereafter, the following has occurred:
On April 15, 2015 we provided an update regarding plans to market Nyloxin® through S.Zhaveri Pharmakem for distribution throughout India. The update stated that our management had been working in Mumbai throughout the week to finalize plans for the national rollout of Nyloxin®.
On April 20, 2015, our stockholders voted at a special meeting of the shareholders held in Coral Springs, Florida to approve a one-for-forty reverse stock split of our issued and outstanding shares of common stock. Under the adopted proposal, each forty shares of our presently issued and outstanding Common Stock as of the close of business on the effective date was converted automatically into one share of our post-Reverse Split Common Stock. Fractional shares and "odd lots" were rounded up to the nearest whole share. The Reverse Split did not change the number of authorized shares of our Common Stock. The principal effect of the Reverse Split was the reduction in the number of shares of Common Stock issued and outstanding, from 1,510,950,321 shares as of March 6, 2015 to 39,123,758 shares after the Reverse Split was deemed effective. The Reverse Split affected all of our shareholders uniformly and did not affect any shareholder’s percentage ownership interest in Nutra or any shareholder’s proportionate voting power. Per share and weighted average amounts have been retroactively restated in the accompanying financial statements and related notes to reflect this stock split.
On April 22, 2015 we announced that we had engaged the Vancouver Commodities Group (VCG) to begin the process of identifying and vetting potential distributors in China for Nyloxin®.
On April 30, 2015 we announced that we had received notification of the acceptance of Nyloxin® by the China International Exchange and Promotive Association for Medical and Healthcare (CPAM). This process was successfully conducted by the Vancouver Commodities Group (VCG) that had been hired by Nutra Pharma to begin the process of identifying and vetting potential distributors in China.
On May 14, 2015 we announced that we had engaged the Nature's Clinic to begin the process of regulatory approval of our Company's Over-the-Counter pain drug, Nyloxin® for marketing and distribution in Canada. The Nature’s Clinic has already begun setting up their Chatham, Ontario warehouse and expect to complete the approval process to begin distributing Nyloxin® by the end of the year.
On May 26, 2015 we announced that we had engaged Medical Strategy Consultants, LLC to aid the company in the filing of Orphan Drug applications with the U.S. Food and Drug Administration ("FDA"). The first application under development is for the treatment of Pediatric Multiple Sclerosis with the Company's lead drug candidate, RPI-78M. In order to create the application, RPI-78M needed to meet several key criteria. This included preclinical data in support of the drug that provided a reasonable rationale for the treatment of the disease based on its potential ability to treat the symptoms of multiple sclerosis. The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics. The Orphan Drug Act of 1983 is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders, defined as those affecting fewer than 200,000 Americans at any given time. The designation of RPI-78M as an Orphan Drug would provide Nutra Pharma with a 7-year period of market exclusivity in the U.S. upon approval of the drug, as well as tax credits for clinical research costs, the ability to apply for grant funding, clinical trial design assistance, assistance from the FDA in the drug development process and the waiver of Prescription Drug User Fee Act (PDUFA) filing fees which could be in excess of $2.5 million. The decision to proceed with an Orphan Drug Designation submission is part of Nutra Pharma's plan to move forward with the preparation of an Investigative New Drug Application.
On June 9, 2015 we announced that we had entered into a facility and personnel sharing agreement with Nationwide Laboratory Services, Inc. (NLS): Nationwide Laboratory Services, Inc. operates as a clinical diagnostics laboratory, performing routine and specialty human diagnostics. The company also offers clinical trial services, such as specimen and special handling requirements, status of test results, turnaround time, testing, participants test results, channeling calls to technical or professional personnel, communicating specimen issues, notifying investigational site of critical calls, and telephone support with data management training services; and courier tracking services. The collaboration provides NLS with the use of our lab space and equipment and provides us with lab and clinical personnel as well as cost-savings on rent and utilities.
On June 23, 2015 we announced that we had completed a series of projects to update and expand the facilities that house the Asian cobras utilized for the production of Nyloxin®. We also announced the addition of 100 snakes to the existing milking line to increase venom production for the upcoming international orders from India and China.
On June 30, 2015 we announced that we had engaged Pickwick Capital Partners; a leading investment banking, securities and investment management firm, to provide strategic corporate planning and investment banking services. Pickwick will focus on assisting Nutra Pharma in our strategies for maximizing shareholder value through its full scope of investment banking services.
On July 10, 2015, SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, announced it has initiated coverage of Nutra Pharma Corporation with a Price Target of $0.53 per share.
On July 15, 2015 we announced that we had filed an application with the FDA for orphan drug status of the Company's RPI-78M drug candidate for the treatment of Multiple Sclerosis in children. This represents the first such filing for the company.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |